应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
BIIB 渤健公司
已收盘 02-02 16:00:00 EST
179.09
-0.80
-0.44%
盘后
179.09
+0.00
0.00%
18:45 EST
最高
180.76
最低
177.58
成交量
128.88万
今开
179.30
昨收
179.89
日振幅
1.77%
总市值
262.73亿
流通市值
261.88亿
总股本
1.47亿
成交额
2.31亿
换手率
0.88%
流通股本
1.46亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
FDA优先审评受理Leqembi®（Lecanemab-Irmb）皮下起始剂量补充生物制剂许可申请，用于早期阿尔茨海默病治疗
美股速递 · 01-26
FDA优先审评受理Leqembi®（Lecanemab-Irmb）皮下起始剂量补充生物制剂许可申请，用于早期阿尔茨海默病治疗
高盛：Leqembi与研发管线支撑增收增利结构性变革，给予百健(BIIB.US)“买入”评级
智通财经 · 01-15
高盛：Leqembi与研发管线支撑增收增利结构性变革，给予百健(BIIB.US)“买入”评级
渤健公司预计第四季度支出2.22亿美元 每股盈利将受1.26美元冲击 股价应声下跌6%
美股速递 · 01-14
渤健公司预计第四季度支出2.22亿美元 每股盈利将受1.26美元冲击 股价应声下跌6%
百健CEO：居家阿尔茨海默症药物具备超越礼来竞争疗法的优势
格隆汇 · 01-14
百健CEO：居家阿尔茨海默症药物具备超越礼来竞争疗法的优势
百健(BIIB.US)押注家用阿尔茨海默病药物 称将成对抗礼来(LLY.US)的“制胜筹码”
智通财经 · 01-14
百健(BIIB.US)押注家用阿尔茨海默病药物 称将成对抗礼来(LLY.US)的“制胜筹码”
渤健公司获欧盟委员会批准Spiranza®高剂量方案用于脊髓性肌萎缩症治疗
美股速递 · 01-13
渤健公司获欧盟委员会批准Spiranza®高剂量方案用于脊髓性肌萎缩症治疗
美国官员称与安进、施贵宝、罗氏旗下基因泰克、吉利德、葛兰素史克、默沙东、诺华、赛诺菲和博瑞诺的交易
美股速递 · 2025-12-20
美国官员称与安进、施贵宝、罗氏旗下基因泰克、吉利德、葛兰素史克、默沙东、诺华、赛诺菲和博瑞诺的交易
纳斯达克宣布渤健、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体、Trade Desk 将退出纳斯达克100指数
投资观察 · 2025-12-13
纳斯达克宣布渤健、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体、Trade Desk 将退出纳斯达克100指数
纳斯达克100指数调整：新增希捷科技等6家公司，剔除安森美半导体等6家公司
老虎资讯综合 · 2025-12-13
纳斯达克100指数调整：新增希捷科技等6家公司，剔除安森美半导体等6家公司
纳斯达克公司：渤健公司、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体及Trade Desk将被剔除出纳斯达克100指数
美股速递 · 2025-12-13
纳斯达克公司：渤健公司、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体及Trade Desk将被剔除出纳斯达克100指数
渤健公司获得加拿大卫生部对Zurzuvae™（Zuranolone）的授权，成为加拿大唯一针对成人产后抑郁症的治疗方案
美股速递 · 2025-12-09
渤健公司获得加拿大卫生部对Zurzuvae™（Zuranolone）的授权，成为加拿大唯一针对成人产后抑郁症的治疗方案
Stoke Therapeutics与渤健公司在2025年美国癫痫学会年会上展示进一步支持Zorevunersen作为Dravet综合症治疗药物的疾病改变潜力的数据
美股速递 · 2025-12-05
Stoke Therapeutics与渤健公司在2025年美国癫痫学会年会上展示进一步支持Zorevunersen作为Dravet综合症治疗药物的疾病改变潜力的数据
Eisai 在2025年阿尔茨海默病临床试验会议上展示 Leqembi®（Lecanemab-Irmb）在早期阿尔茨海默病持续和扩展益处的新数据
美股速递 · 2025-12-04
Eisai 在2025年阿尔茨海默病临床试验会议上展示 Leqembi®（Lecanemab-Irmb）在早期阿尔茨海默病持续和扩展益处的新数据
2025年阿尔茨海默病临床试验会议上公布的新数据确认Leqembi® (Lecanemab-Irmb)对脑脊液中神经毒性aβ原纤维的药理作用
美股速递 · 2025-12-03
2025年阿尔茨海默病临床试验会议上公布的新数据确认Leqembi® (Lecanemab-Irmb)对脑脊液中神经毒性aβ原纤维的药理作用
Eisai完成对美国FDA的Leqembi® Iqlik™（Lecanemab-Irmb）补充生物制剂许可申请的滚动提交，作为早期阿尔茨海默病的皮下注射启动剂量，已获得快速通道状态
美股速递 · 2025-11-25
Eisai完成对美国FDA的Leqembi® Iqlik™（Lecanemab-Irmb）补充生物制剂许可申请的滚动提交，作为早期阿尔茨海默病的皮下注射启动剂量，已获得快速通道状态
渤健公司与Dayra Therapeutics宣布研究合作，开发用于多种免疫疾病的口服大环肽
美股速递 · 2025-11-24
渤健公司与Dayra Therapeutics宣布研究合作，开发用于多种免疫疾病的口服大环肽
诺和诺德新疗法受挫，竞争对手渤健盘前拉升
老虎资讯综合 · 2025-11-24
诺和诺德新疗法受挫，竞争对手渤健盘前拉升
努西瑞辛高剂量方案获得CHMP积极意见，用于治疗脊髓性肌萎缩症
美股速递 · 2025-11-17
努西瑞辛高剂量方案获得CHMP积极意见，用于治疗脊髓性肌萎缩症
一周美股牛榜 | 美国雅保周涨18%，获大行高看至107美元；礼来升近11%，本周创新高；思科周内涨10%
老虎资讯综合 · 2025-11-17
一周美股牛榜 | 美国雅保周涨18%，获大行高看至107美元；礼来升近11%，本周创新高；思科周内涨10%
异动解读 | 渤健公司下调全年利润预期，盘前股价大跌5.65%
异动解读 · 2025-10-30
异动解读 | 渤健公司下调全年利润预期，盘前股价大跌5.65%
加载更多
公司概况
公司名称：
渤健公司
所属市场：
NASDAQ
上市日期：
--
主营业务：
Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司，专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症（MS）和神经免疫学；阿尔茨海默病（AD）和痴呆症；神经肌肉疾病，包括脊髓肌萎缩症（SMA）和肌萎缩侧索硬化症（ALS）；运动障碍，包括帕金森氏症；以及眼科学。该公司还专注于在免疫学、神经认知障碍、急性神经学和疼痛等新兴增长领域发现、开发和提供全球创新疗法。
发行价格：
--
{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":179.09,"timestamp":1770066000000,"preClose":179.89,"halted":0,"volume":1288811,"hourTrading":{"tag":"盘后","latestPrice":179.09,"preClose":179.09,"latestTime":"18:45 EST","volume":30308,"amount":5427897.45,"timestamp":1770075919262,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.004447162154649969,"floatShares":146226846,"shares":146702272,"eps":10.974839,"marketStatus":"已收盘","change":-0.8,"latestTime":"02-02 16:00:00 EST","open":179.3,"high":180.7599,"low":177.58,"amount":230752884.29953,"amplitude":0.017677,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":10.974839,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770109200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":685080000000,"exchange":"NASDAQ","adjPreClose":179.89,"preHourTrading":{"tag":"盘前","latestPrice":180.11,"preClose":179.89,"latestTime":"09:24 EST","volume":824,"amount":147067.52,"timestamp":1770042275570,"change":0.22,"changeRate":0.001223,"amplitude":0.02307},"postHourTrading":{"tag":"盘后","latestPrice":179.09,"preClose":179.09,"latestTime":"18:45 EST","volume":30308,"amount":5427897.45,"timestamp":1770075919262,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.12332,"impliedVol":0.332,"impliedVolPercentile":0.1793},"requestUrl":"/m/hq/s/BIIB","defaultTab":"news","newsList":[{"id":"1164132348","title":"FDA优先审评受理Leqembi®（Lecanemab-Irmb）皮下起始剂量补充生物制剂许可申请，用于早期阿尔茨海默病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1164132348","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164132348?lang=zh_cn&edition=full","pubTime":"2026-01-26 07:30","pubTimestamp":1769383838,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理渤健公司旗下Leqembi®（Lecanemab-Irmb）的补充生物制剂许可申请，将其皮下注射起始剂量方案纳入优先审评通道，用于治疗早期阿尔茨海默病。此次审评聚焦于该疗法在给药方式上的创新突破，有望为患者提供更便捷的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BK4533","BK4585","IE00B894F039.SGD","LU0320765992.SGD","BK4139","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BK4532","LU0889565916.HKD","LU0109394709.USD","BIIB","BK4588"],"gpt_icon":0},{"id":"2603608825","title":"高盛：Leqembi与研发管线支撑增收增利结构性变革，给予百健(BIIB.US)“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2603608825","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603608825?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:10","pubTimestamp":1768468236,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛在与百健管理层会面后，给予其“买入”评级，目标价225美元。高盛表示，百健管理层强调了公司文化向专注于研发和费用控制的转变，这是其战略的一部分，旨在抵消多发性硬化症业务的下滑并推动增长。总而言之，高盛认为百健今年有望迎来转折点，这得益于研发管线催化剂和Leqembi的推动，以及严格的成本控制和优先发展早期罕见病和/或免疫学资产的合理业务发展策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"高盛：Leqembi与研发管线支撑增收增利结构性变革，给予百健(BIIB.US)“买入”评级","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIIB"],"gpt_icon":0},{"id":"1133463005","title":"渤健公司预计第四季度支出2.22亿美元 每股盈利将受1.26美元冲击 股价应声下跌6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133463005","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133463005?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:24","pubTimestamp":1768404264,"startTime":"0","endTime":"0","summary":"渤健公司股价大幅下挫6%，此前该公司宣布预计第四季度将产生2.22亿美元的特殊支出。这笔一次性费用预计将使每股收益减少1.26美元，对当季盈利能力构成显著压力。\n市场对此消息反应迅速，投资者纷纷抛售股票，导致股价出现明显波动。此次支出预计将直接影响公司第四季度的财务表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0109394709.USD","BK4532","BK4533","BK4585","LU0320765992.SGD","IE00B19Z9P08.USD","LU0889565916.HKD","LU0234570918.USD","BK4139","IE00B19Z9Z06.USD","BIIB","IE00B894F039.SGD"],"gpt_icon":0},{"id":"2603619522","title":"百健CEO：居家阿尔茨海默症药物具备超越礼来竞争疗法的优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2603619522","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603619522?lang=zh_cn&edition=full","pubTime":"2026-01-14 21:28","pubTimestamp":1768397307,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BJT1NW94.SGD","LU0203202063.USD","LU1868837136.USD","LU1280957306.USD","LU2112291526.USD","LU0256863902.USD","LU0786609619.USD","LU2237438978.USD","LU2491050154.USD","BK4599","IE00B1BXHZ80.USD","LU1868836591.USD","LU0094547139.USD","LU1551013425.SGD","LU2236285917.USD","LU0683600562.USD","LU2063271972.USD","IE0004445239.USD","SGXZ51526630.SGD","LU2462157665.USD","BK4007","LU0203201768.USD","IE00B7KXQ091.USD","IE00BKDWB100.SGD","LU0198837287.USD","LU2361044949.HKD","LU2108987350.USD","SG9999014898.SGD","BK4534","LU1804176565.USD","LU0096364046.USD","LU2552382215.SGD","LU1868836757.USD","LU1983299246.USD","LU2237443382.USD","LU0225283273.USD","SG9999001176.USD","LU2324357040.USD","LU1868836914.USD","SG9999018857.SGD","IE0002141913.USD","LU2237443895.HKD","LU1323610961.USD","IE00B2B36J28.USD","LU0417517546.SGD","LU2552382058.USD","SG9999014914.USD","LU1989771016.USD","LU2750360997.AUD","SGXZ99366536.SGD","LU0114720955.EUR","LU0320765059.SGD","LU0889565916.HKD","LU1023059063.AUD","LU2491050071.SGD","LU0820561909.HKD","IE00BJJMRZ35.SGD","SG9999015986.USD","LLY","SGXZ57979304.SGD","BK4588","LU1093756168.USD","LU1974910355.USD","LU2360106947.USD","LU1917777945.USD","GB00BDT5M118.USD","SG9999017495.SGD","LU1064131342.USD","IE00BJLML261.HKD","LU0006306889.USD","LU0097036916.USD","LU0266013472.USD","LU2602419157.SGD","LU1061106388.HKD","LU0353189680.USD","IE00BFSS7M15.SGD","LU1267930730.SGD","LU0708995401.HKD","LU0353189763.USD","LU0289739699.SGD","LU0820561818.USD","LU1366192091.USD","SG9999018865.SGD","BIIB","LU2168563687.JPY","LU1232071149.USD","LU0471298777.SGD","LU0466842654.USD","LU1720051108.HKD","BK4516","LU2264538146.SGD","LU1868837300.USD","LU0672654240.SGD","LU2471134952.CNY","LU0316494557.USD","LU2456880835.USD","SG9999015952.SGD","LU1291159041.SGD","LU0256863811.USD","LU2471134796.USD","LU2265009873.SGD","LU0109391861.USD","LU1035775433.USD","LU2237443549.SGD","LU2417539215.USD","LU1988902786.USD","IE00BJJMRY28.SGD","LU0354030438.USD","LU2750360641.GBP","IE00BN29S564.USD","LU2237443978.SGD","SG9999001176.SGD","LU2746668461.USD","SGXZ31699556.SGD","SG9999015978.USD","LU0432979614.USD","LU0061475181.USD","LU0689472784.USD","LU0823434583.USD","IE00BK4W5L77.USD","IE00B4R5TH58.HKD","LU2106854487.HKD","LU2023250504.SGD","LU2168564149.EUR","LU0471298694.HKD","LU0823434740.USD","LU0079474960.USD","SGXZ81514606.USD","BK4533","LU2357305700.SGD","LU0943347566.SGD","LU2552382132.HKD","SG9999014906.USD","SG9999015945.SGD","LU0058720904.USD","LU2237443622.USD","LU0323591593.USD","LU2361044865.SGD","LU0882574055.USD","BK4585","LU1069344957.HKD","LU0109394709.USD","IE00BKPKM429.USD","LU0122379950.USD","LU2089984988.USD","IE00BWXC8680.SGD","LU0456855351.SGD","SG9999014880.SGD","LU1720051017.SGD","LU1623119135.USD","LU2746668974.SGD","LU2087625088.SGD","IE00B4JS1V06.HKD","LU0787776722.HKD","LU2471134879.HKD","IE00BK4W5M84.HKD","IE0004445015.USD","IE00BJJMRX11.SGD","LU0640476718.USD","LU1057294990.SGD","IE00B1XK9C88.USD","LU0354030511.USD","BK4581","LU0234572021.USD","LU0320765992.SGD","LU0385154629.USD","LU1127390331.HKD","LU1548497426.USD","LU1093756325.SGD","LU0238689110.USD","LU1712237335.SGD","SG9999013999.USD","LU0882574139.USD","LU0823416689.USD","IE0009355771.USD","LU1551013342.USD","LU2168564065.EUR","LU2461242641.AUD","LU0106261372.USD","IE00BFSS8Q28.SGD","LU2491049909.HKD","LU2168564222.USD","LU2237443465.HKD","LU2468319806.SGD","LU2211815571.USD","LU1814569148.SGD","IE00B775H168.HKD","LU2168564495.EUR","IE0005OL40V9.USD","IE00BFTCPJ56.SGD","LU2361045086.USD","LU2471134523.USD"],"gpt_icon":0},{"id":"2603514619","title":"百健(BIIB.US)押注家用阿尔茨海默病药物 称将成对抗礼来(LLY.US)的“制胜筹码”","url":"https://stock-news.laohu8.com/highlight/detail?id=2603514619","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603514619?lang=zh_cn&edition=full","pubTime":"2026-01-14 21:24","pubTimestamp":1768397046,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在阿尔茨海默病新药市场竞争白热化之际，百健公司首席执行官克里斯·维巴赫近日表示，其与卫材合作开发的Leqembi家用注射剂型将成为公司对抗竞争对手礼来同类疗法的“关键优势”。相比之下，礼来的药物目前尚未提供家用给药选择。温和增长百健的投资者正密切关注Leqembi的市场推广情况。百健预计将于2028年公布该试验的结果。维巴赫说，“这几乎无疑是阿尔茨海默病治疗的未来方向。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014914.USD","LU2471134796.USD","LU1551013342.USD","BK4585","LU2168563687.JPY","LU1868836757.USD","SG9999001176.USD","LU2211815571.USD","BK4007","LU1712237335.SGD","LU2462157665.USD","LU1057294990.SGD","LU2168564065.EUR","SG9999018865.SGD","LU0820561909.HKD","LU1988902786.USD","LU1720051017.SGD","SG9999014898.SGD","LU0943347566.SGD","LU2491050071.SGD","SG9999001176.SGD","IE00B19Z9Z06.USD","IE0005OL40V9.USD","LU0683600562.USD","LU2237443465.HKD","LU0823434740.USD","GB00BDT5M118.USD","SGXZ57979304.SGD","LU0823434583.USD","SGXZ51526630.SGD","BK4581","LU0889565916.HKD","LU2237443895.HKD","IE00BKPKM429.USD","LU0882574139.USD","LU0786609619.USD","SG9999014906.USD","IE00BKDWB100.SGD","LU0106261372.USD","LU0323591593.USD","LU0820561818.USD","LU0058720904.USD","BK4588","LU0353189763.USD","LU0787776722.HKD","LU1868837300.USD","LU1093756168.USD","LU0672654240.SGD","LU2237438978.USD","LU2360106947.USD","LU0823416689.USD","LU2237443978.SGD","LU1868836591.USD","LU2087625088.SGD","LU2471134523.USD","IE00BJJMRY28.SGD","LU2361044949.HKD","BK4534","LU0225283273.USD","LU0320765059.SGD","LU2168564495.EUR","LU0471298777.SGD","BK4139","LU0354030511.USD","LU0096364046.USD","LLY","IE00BJJMRX11.SGD","LU0640476718.USD","IE00BN29S564.USD","LU2168564222.USD","LU0094547139.USD","LU2552382132.HKD","LU0109391861.USD","LU0114720955.EUR","LU2237443622.USD","IE00BFTCPJ56.SGD","LU2023250504.SGD","SG9999015986.USD","LU0353189680.USD","SGXZ99366536.SGD","LU2106854487.HKD","LU2471134952.CNY","LU1868836914.USD","LU1548497426.USD","LU0234570918.USD","LU0471298694.HKD","LU0708995401.HKD","LU0097036916.USD","LU1804176565.USD","BIIB","LU0203202063.USD","LU2417539215.USD","LU2357305700.SGD","LU0316494557.USD","IE0002141913.USD","IE00B4JS1V06.HKD","IE00BFSS7M15.SGD","SG9999013999.USD","LU1267930730.SGD","LU0689472784.USD","LU1814569148.SGD","LU1023059063.AUD","IE00B1XK9C88.USD","IE00BK4W5M84.HKD","BK4516","IE00BWXC8680.SGD","LU1974910355.USD","LU2361044865.SGD","SG9999014880.SGD","LU0432979614.USD","LU2471134879.HKD","IE00BJT1NW94.SGD","LU2552382058.USD","LU0266013472.USD","LU2750360641.GBP","LU1989771016.USD","LU1064131342.USD","SG9999017495.SGD","LU2236285917.USD","LU2491049909.HKD","LU0198837287.USD","LU2456880835.USD","LU2089984988.USD","IE00B4R5TH58.HKD","LU1623119135.USD","LU2112291526.USD","SGXZ31699556.SGD","LU0234572021.USD","IE00B775H168.HKD","LU0079474960.USD","LU0256863902.USD","LU1551013425.SGD","LU1280957306.USD","LU2361045086.USD","LU0061475181.USD","LU1917777945.USD","LU2491050154.USD","BK4532","LU1983299246.USD","IE00BK4W5L77.USD","LU2746668974.SGD","LU2265009873.SGD","LU0882574055.USD","LU1323610961.USD","LU0456855351.SGD","LU0109394709.USD","LU2264538146.SGD","LU2324357040.USD","IE00BJJMRZ35.SGD","BK4533","IE00B19Z9P08.USD","IE0009355771.USD","IE00B7KXQ091.USD","IE00B894F039.SGD","LU1868837136.USD","LU0256863811.USD","LU0354030438.USD","LU1069344957.HKD","LU0385154629.USD","LU0203201768.USD","LU2468319806.SGD","LU2746668461.USD","IE0004445015.USD","LU1291159041.SGD","LU2552382215.SGD","IE00B2B36J28.USD","LU1720051108.HKD","LU1127390331.HKD","LU1366192091.USD","LU0122379950.USD","LU2168564149.EUR","IE00B1BXHZ80.USD","IE0004445239.USD","IE00BFSS8Q28.SGD","LU1232071149.USD","LU0289739699.SGD","LU1061106388.HKD","LU2750360997.AUD","IE00BJLML261.HKD","LU0320765992.SGD","SGXZ81514606.USD","SG9999015952.SGD","LU2237443382.USD","LU2602419157.SGD","LU0466842654.USD","LU1035775433.USD","LU2108987350.USD","LU2063271972.USD","LU1093756325.SGD","SG9999015978.USD","SG9999015945.SGD","LU2461242641.AUD","SG9999018857.SGD","LU2237443549.SGD","LU0238689110.USD","BK4599","LU0417517546.SGD","LU0006306889.USD"],"gpt_icon":1},{"id":"1145314898","title":"渤健公司获欧盟委员会批准Spiranza®高剂量方案用于脊髓性肌萎缩症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1145314898","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145314898?lang=zh_cn&edition=full","pubTime":"2026-01-13 00:11","pubTimestamp":1768234293,"startTime":"0","endTime":"0","summary":"欧盟委员会已正式批准渤健公司针对脊髓性肌萎缩症的Spiranza®（Nusinersen）高剂量治疗方案。这一监管里程碑标志着该疗法在欧盟市场获得重要拓展，为患者群体提供更具灵活性的用药选择。\n此次获批的高剂量方案将进一步提升药物在临床实践中的应用价值，凸显渤健公司在神经科学治疗领域持续创新的战略布局。监管机构的认可也为该疗法在更广泛患者群体中的使用铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","IONS","BK4533","LU0234570918.USD","BK4139","LU0320765992.SGD","LU0889565916.HKD","BIIB","BK4585","BK4588","IE00B894F039.SGD","LU0109394709.USD","IE00B19Z9P08.USD","BK4532"],"gpt_icon":0},{"id":"1190397083","title":"美国官员称与安进、施贵宝、罗氏旗下基因泰克、吉利德、葛兰素史克、默沙东、诺华、赛诺菲和博瑞诺的交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1190397083","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190397083?lang=zh_cn&edition=full","pubTime":"2025-12-20 03:22","pubTimestamp":1766172127,"startTime":"0","endTime":"0","summary":"美国官员称与安进、施贵宝、罗氏旗下基因泰克、吉利德、葛兰素史克、默沙东、诺华、赛诺菲和博瑞诺的交易","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU1323610961.USD","IE00B2B36J28.USD","LU0122379950.USD","GILD","BK4585","LU1116320901.HKD","BIIB","LU2089984988.USD","LU0267386448.USD","SG9999014567.USD","LU2361045086.USD","LU1670711123.USD","SG9999002224.SGD","LU0823416689.USD","IE00BQJZX424.USD","IE00BSNM7G36.USD","SNY","LU1023059063.AUD","LU0114720955.EUR","SG9999014559.SGD","BK4534","LU1778281490.HKD","LU2023250504.SGD","LU0980610538.SGD","LU1974910355.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0203345920.USD","LU1868836757.USD","LU0266013472.USD","LU0289739699.SGD","LU2125154778.USD","LU0321505868.SGD","LU1098665638.USD","LU0234572021.USD","LU1670710661.SGD","SG9999001176.SGD","LU1057294990.SGD","LU1162221912.USD","LU1309081286.SGD","IE00B3T34201.USD","IE0002270589.USD","BK4599","LU0130517989.USD","LU1064927863.SGD","LU1868837300.USD","LU1839511570.USD","LU2324357040.USD","LU0225771236.USD","LU1571399168.USD","LU2361044865.SGD","SGXZ57979304.SGD","LU0225284248.USD","LU0106261372.USD","LU0109394709.USD","LU0234570918.USD","LU1228905540.USD","LU0965509101.SGD","LU1868837136.USD","SG9999015978.USD","LU1934455194.USD","LU0320765992.SGD","IE00BWDBJ516.SGD","BK4568","MRK","SG9999014575.USD","SG9999015945.SGD","IE00BLSP4239.USD","LU1116320737.USD","SG9999015341.SGD","LU0161305163.EUR","LU1037948897.HKD","LU1066051498.USD","LU1941712348.USD","LU0321505439.SGD","LU0237698245.USD","IE00BLSP4452.SGD","LU0477156953.USD","LU0985481810.HKD","IE00BKVL7J92.USD","LU2242646821.SGD","LU0265550359.USD","LU0965508806.USD","LU1941712264.USD","LU2133065610.SGD","LU0238689110.USD","BK4516","BK4581","LU0058720904.USD","LU0545562505.USD","LU1035777561.USD","SG9999015952.SGD","LU1202635105.USD","IE00B1BXHZ80.USD","LU0306806265.USD","LU0211331839.USD","LU2112291526.USD","LU0006306889.USD","LU2023250843.SGD","BK4139","NVS","LU0203347892.USD","LU1699723380.USD","LU0648001328.SGD","LU2468319806.SGD","LU0109981661.USD","LU1670710588.SGD","IE00B19Z3581.USD","LU1989771016.USD","IE0009355771.USD","LU1302929846.USD","IE000M9KFDE8.USD","LU1487256676.USD","IE0034235071.USD","LU1670756490.USD","BK4550","LU1989772923.USD","IE00BZ1G4Q59.USD","LU1069347547.HKD","BK4578","BK4559","BK4532","IE00BJJMRZ35.SGD","LU1066051225.USD","LU1061106388.HKD","LU2087621335.USD","LU2361044949.HKD","RHHBY","GSK","LU0061475181.USD","LU2106854487.HKD","LU1917777945.USD","BK5011","LU1291159041.SGD","LU1989772840.SGD","LU1645745479.HKD","IE00BJT1NW94.SGD","LU0971552673.USD","LU1929549753.HKD","LU0320765646.SGD","LU1481600234.SGD","LU1718418525.SGD","LU2360032135.SGD","LU1670711040.USD","LU1046248800.SGD","LU0965509283.SGD","LU1015430645.USD","BK4588","LU2461242641.AUD","BK4566","LU1066053197.SGD","LU0130102774.USD","LU1983299246.USD","SG9999015358.SGD","LU1400636491.USD","IE0002141913.USD","LU0985320562.USD","LU1400636574.HKD","LU1400636657.SGD","LU1674673428.USD","LU0868494617.USD","IE00B19Z3B42.SGD","LU1093756325.SGD","LU1674673691.USD","04332","LU1201861249.SGD","LU0456855351.SGD","LU0965509010.AUD","LU1934455863.HKD","LU0208291251.USD","LU0861579265.USD","BK4583","SG9999014542.SGD","LU0882574055.USD","LU1481599808.USD","LU1868836591.USD","LU1228905037.USD","LU1585245621.USD","IE00BN8TJ469.HKD","LU1934455277.USD","LU1261432733.SGD","LU1066051811.HKD","LU1093756168.USD","IE00B7SZLL34.SGD","LU0971552830.HKD","IE00BFXG1179.USD","BK4533","LU1074936037.SGD","LU1868836914.USD","LU1035773651.USD","SG9999001176.USD","LU1037948541.HKD","LU0320765489.SGD","LU1430594728.SGD","BMY","BK4007","LU0070302665.USD","LU0098860793.USD","SG9999002232.USD","LU1032466523.USD","SG9999013999.USD","SG9999001440.SGD","LU2242652126.USD","IE00BBT3K403.USD","LU0265550946.USD","LU0575583348.USD","AMGN","LU0306807586.USD","LU2125154935.USD","SG9999015986.USD","LU0096364046.USD"],"gpt_icon":0},{"id":"1166333259","title":"纳斯达克宣布渤健、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体、Trade Desk 将退出纳斯达克100指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1166333259","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166333259?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:21","pubTimestamp":1765588891,"startTime":"0","endTime":"0","summary":"12月12日（路透社）- 纳斯达克公司宣布：*纳斯达克公司 - 宣布纳斯达克100指数的重组，将于12月22日生效* 纳斯达克公司：六家公司将被添加到纳斯达克100指数* 纳斯达克公司：渤健、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体、Trade Desk 将退出纳斯达克100指数* 纳斯达克公司：阿尔尼拉姆制药公司、FERROVIAL、INSMED、Monolithic Power Systems、希捷科技、西部数据将被添加到纳斯达克100指数。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"379c269ef09dde4ff2ea787d7ec186f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1046421795.USD","CDW","LU1854104046.USD","IE00B19Z9Z06.USD","LU0823411888.USD","LU0672654240.SGD","ALNY","LU0348723411.USD","WDC","BK4613","LU1815336760.USD","LU0109394709.USD","LU0124384867.USD","LU1823568750.SGD","STX","LU2360107325.USD","LU1720051108.HKD","BK4605","LU0006061336.USD","LU0109391861.USD","BK4588","BK4202","LU0081259029.USD","LU2089985449.USD","LU2931357623.SGD","IE00BZ199S13.USD","LU0203345920.USD","LU2360107168.USD","LU2322448957.HKD","LU0320765992.SGD","LU2272731865.HKD","LU1267930730.SGD","LU1852331112.SGD","LU0320765059.SGD","LULU","LU1992135399.USD","LU2087625088.SGD","LU2272731600.USD","LU0353189680.USD","LU1854103824.USD","BK4532","LU0056508442.USD","LU1670627923.USD","BK4170","LU2473716301.USD","LU1861219969.SGD","BIIB","LU1670628061.USD","IE00BN0W2V16.EUR","LU1861220033.SGD","IE00B894F039.SGD","BK4141","LU0274383776.USD","BK4533","LU0234570918.USD","BK4139","LU0724618433.USD","LU1496350502.SGD","BK4548","LU2290526834.HKD","LU2250418816.HKD","LU1035773651.USD","LU2298322129.HKD","IE00BN0W2W23.USD","LU1861214812.USD","BK4023","LU2272731782.SGD","IE00BN0W2T93.GBP","IE00BFMHRM44.USD","LU1992135472.HKD","LU0882574055.USD","BK4512","BK4140","GFS","MPWR","BK4504","LU0708995401.HKD","LU0444973449.USD","LU0476273544.USD","LU0353189763.USD","LU1861215975.USD","LU0114720955.EUR","LU1642822529.SGD","LU0444971666.USD","BK4528","LU1978683503.SGD","IE00B19Z9P08.USD","LU0957808578.USD","TTD","LU1720051017.SGD","LU0889565916.HKD","IE00BD6J9T35.USD","LU1069347547.HKD","LU2357305700.SGD","BK4585","BK4009","LU1548497426.USD","LU2322448791.USD","ON","LU1235294995.USD","LU2360106780.USD","LU0203347892.USD"],"gpt_icon":0},{"id":"1117266784","title":"纳斯达克100指数调整：新增希捷科技等6家公司，剔除安森美半导体等6家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1117266784","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117266784?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:08","pubTimestamp":1765588106,"startTime":"0","endTime":"0","summary":"12月13日，纳斯达克公司宣布纳斯达克100指数成份股调整将于12月22日生效。6家公司即将被纳入纳斯达克100指数。分别是艾尼拉姆制药公司、费罗维亚集团、英斯梅德公司、单片电源系统公司、希捷科技控股有限公司和西部数据公司。而有6家被移出，百健公司（Biogen）CDW公司、格芯公司、露露乐蒙、安森美半导体和交易台公司（The Trade Desk）。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"379c269ef09dde4ff2ea787d7ec186f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"纳斯达克100指数调整：新增希捷科技等6家公司，剔除安森美半导体等6家公司","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDC","ON","FER","NDAQ","TTD","ALNY","LULU","BIIB","GFS","CDW","MPWR","STX"],"gpt_icon":0},{"id":"1141399315","title":"纳斯达克公司：渤健公司、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体及Trade Desk将被剔除出纳斯达克100指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1141399315","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141399315?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:04","pubTimestamp":1765587854,"startTime":"0","endTime":"0","summary":"纳斯达克公司：渤健公司、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体及Trade Desk将被剔除出纳斯达克100指数","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"379c269ef09dde4ff2ea787d7ec186f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0724618433.USD","BK4140","BK4141","SG9999014039.USD","LU2095319765.USD","SG9999014021.USD","IE00B3QW5Z07.USD","LU1854104046.USD","BK4009","NDAQ","BK4585","BK4504","IE00BGHQF748.EUR","LULU","LU1720051017.SGD","LU1496350502.SGD","BK4023","LU2210150020.SGD","SG9999014005.SGD","LU1854103824.USD","LU2357305700.SGD","SG9999014013.SGD","BK4112","LU0823411888.USD","LU1861215975.USD","LU0320765992.SGD","BK4533","GFS","IE00B894F039.SGD","TTD","BK4548","BIIB","BK4139","LU0109394709.USD","LU0234570918.USD","LU1978683503.SGD","LU0124384867.USD","IE00BFMHRM44.USD","LU1861214812.USD","BK4528","LU1861219969.SGD","LU1861220033.SGD","LU1720051108.HKD","IE00B19Z9Z06.USD","IE00B64PRP62.GBP","LU0314104364.USD","LU2298322129.HKD","IE00BD6J9T35.USD","LU0348723411.USD","BK4613","CDW","BK4605","IE00BKPKM429.USD","BK4202","ON","IE00B19Z9P08.USD","LU0889565916.HKD","LU2360107325.USD","BK4512","BK4588","LU1548497426.USD","LU2210149790.SGD","IE00BZ199S13.USD"],"gpt_icon":0},{"id":"1190730879","title":"渤健公司获得加拿大卫生部对Zurzuvae™（Zuranolone）的授权，成为加拿大唯一针对成人产后抑郁症的治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1190730879","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190730879?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:03","pubTimestamp":1765281816,"startTime":"0","endTime":"0","summary":"渤健公司获得加拿大卫生部对Zurzuvae™（Zuranolone）的授权，成为加拿大唯一针对成人产后抑郁症的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0109394709.USD","BK4532","BK4533","BK4585","LU0320765992.SGD","IE00B19Z9P08.USD","LU0889565916.HKD","LU0234570918.USD","BK4139","IE00B19Z9Z06.USD","BIIB","IE00B894F039.SGD"],"gpt_icon":0},{"id":"1149660254","title":"Stoke Therapeutics与渤健公司在2025年美国癫痫学会年会上展示进一步支持Zorevunersen作为Dravet综合症治疗药物的疾病改变潜力的数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1149660254","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149660254?lang=zh_cn&edition=full","pubTime":"2025-12-05 22:00","pubTimestamp":1764943218,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics与渤健公司在2025年美国癫痫学会年会上展示进一步支持Zorevunersen作为Dravet综合症治疗药物的疾病改变潜力的数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","LU0889565916.HKD","BK4532","BK4588","BK4139","IE00B19Z9Z06.USD","LU0109394709.USD","LU0234570918.USD","BK4585","STOK","LU0320765992.SGD","BIIB","IE00B894F039.SGD","BK4533"],"gpt_icon":0},{"id":"1166943636","title":"Eisai 在2025年阿尔茨海默病临床试验会议上展示 Leqembi®（Lecanemab-Irmb）在早期阿尔茨海默病持续和扩展益处的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1166943636","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166943636?lang=zh_cn&edition=full","pubTime":"2025-12-04 07:11","pubTimestamp":1764803473,"startTime":"0","endTime":"0","summary":"Eisai 在2025年阿尔茨海默病临床试验会议上展示 Leqembi®（Lecanemab-Irmb）在早期阿尔茨海默病持续和扩展益处的新数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BK4533","BK4585","IE00B894F039.SGD","LU0320765992.SGD","BK4139","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BK4532","LU0889565916.HKD","LU0109394709.USD","BIIB","BK4588"],"gpt_icon":0},{"id":"1183487643","title":"2025年阿尔茨海默病临床试验会议上公布的新数据确认Leqembi® (Lecanemab-Irmb)对脑脊液中神经毒性aβ原纤维的药理作用","url":"https://stock-news.laohu8.com/highlight/detail?id=1183487643","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183487643?lang=zh_cn&edition=full","pubTime":"2025-12-03 05:40","pubTimestamp":1764711612,"startTime":"0","endTime":"0","summary":"2025年阿尔茨海默病临床试验会议上公布的新数据确认Leqembi® (Lecanemab-Irmb)对脑脊液中神经毒性aβ原纤维的药理作用","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","BIIB","BK4533","LU0109394709.USD","BK4588","IE00B894F039.SGD","BK4585","BK4139","BK4532","LU0320765992.SGD","LU0889565916.HKD","IE00B19Z9Z06.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"1180289642","title":"Eisai完成对美国FDA的Leqembi® Iqlik™（Lecanemab-Irmb）补充生物制剂许可申请的滚动提交，作为早期阿尔茨海默病的皮下注射启动剂量，已获得快速通道状态","url":"https://stock-news.laohu8.com/highlight/detail?id=1180289642","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180289642?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:30","pubTimestamp":1764073823,"startTime":"0","endTime":"0","summary":"Eisai完成了对美国FDA的Leqembi® Iqlik™（Lecanemab-Irmb）补充生物制剂许可申请的滚动提交，该申请涉及作为早期阿尔茨海默病治疗的皮下注射启动剂量，并已获得快速通道资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","IE00B894F039.SGD","IE00B19Z9Z06.USD","LU0109394709.USD","LU0320765992.SGD","IE00B19Z9P08.USD","LU0889565916.HKD","BK4585","BK4588","LU0234570918.USD","BK4139","BIIB","BK4533"],"gpt_icon":0},{"id":"1137409579","title":"渤健公司与Dayra Therapeutics宣布研究合作，开发用于多种免疫疾病的口服大环肽","url":"https://stock-news.laohu8.com/highlight/detail?id=1137409579","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137409579?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:31","pubTimestamp":1763987497,"startTime":"0","endTime":"0","summary":"渤健公司与Dayra Therapeutics宣布建立研究合作伙伴关系，旨在发现并开发用于治疗多种免疫疾病的口服大环肽。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","IE00B19Z9Z06.USD","IE00B894F039.SGD","BK4532","BK4588","IE00B19Z9P08.USD","LU0234570918.USD","LU0889565916.HKD","BK4585","BK4139","LU0109394709.USD","BK4533","LU0320765992.SGD"],"gpt_icon":0},{"id":"1167349174","title":"诺和诺德新疗法受挫，竞争对手渤健盘前拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=1167349174","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167349174?lang=zh_cn&edition=full","pubTime":"2025-11-24 19:51","pubTimestamp":1763985109,"startTime":"0","endTime":"0","summary":"新疗法未显示出阿尔茨海默病减缓效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c4dd3317d59b6ed3d7569f1d532c0719","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"gpt_icon":0},{"id":"1116946595","title":"努西瑞辛高剂量方案获得CHMP积极意见，用于治疗脊髓性肌萎缩症","url":"https://stock-news.laohu8.com/highlight/detail?id=1116946595","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116946595?lang=zh_cn&edition=full","pubTime":"2025-11-17 19:01","pubTimestamp":1763377303,"startTime":"0","endTime":"0","summary":"努西瑞辛高剂量方案获得CHMP积极意见，用于治疗脊髓性肌萎缩症","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4532","LU0234570918.USD","LU0889565916.HKD","BK4139","IE00B19Z9Z06.USD","IE00B894F039.SGD","LU0109394709.USD","IE00B19Z9P08.USD","BK4588","BIIB","BK4585","BK4533"],"gpt_icon":0},{"id":"1144209379","title":"一周美股牛榜 | 美国雅保周涨18%，获大行高看至107美元；礼来升近11%，本周创新高；思科周内涨10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144209379","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144209379?lang=zh_cn&edition=full","pubTime":"2025-11-17 10:48","pubTimestamp":1763347698,"startTime":"0","endTime":"0","summary":"瑞穗证券将其目标价从92美元上调至110美元，瑞银将其目标价从85美元上调至107美元。礼来升10%，股票本周创历史新高礼来公司的股票本周达到历史新高，达到每股1025美元，此前几笔重大交易促使美国食品和药物管理局对其备受期待的减肥药orforglipron进行了快速审查。","market":"us","thumbnail":"https://community-static.tradeup.com/news/b709e81a1b4f7405bf5e343b3c9425a7","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/b709e81a1b4f7405bf5e343b3c9425a7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"aad815d0c6beee6ce1e194810f0ba331","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALB","BIIB","DVN","ABBV","MRK","BDX","IFF","LLY","CSCO","VRTX"],"gpt_icon":1},{"id":"1180995314","title":"异动解读 | 渤健公司下调全年利润预期，盘前股价大跌5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180995314","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180995314?lang=zh_cn&edition=full","pubTime":"2025-10-30 21:30","pubTimestamp":1761831039,"startTime":"0","endTime":"0","summary":"周四盘前交易中，渤健公司股价大幅下跌5.65%，引发市场关注。消息面上，渤健公司下调了2025年的全年利润预期。公司表示，预计第四季度某些与收购相关的研发支出将导致每股利润下降1.25美元。渤健公司将2025年调整后每股利润预期从此前的15.50美元至16.00美元区间，下调至14.50美元至15.00美元之间。尽管渤健公司第三季度业绩表现亮眼，每股收益达4.81美元，远超分析师平均预期的3.88美元，但下调全年利润预期的消息仍然对股价造成了显著影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIIB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biogen.com","stockEarnings":[{"period":"1week","weight":0.0484},{"period":"1month","weight":0.0222},{"period":"3month","weight":0.1661},{"period":"6month","weight":0.3633},{"period":"1year","weight":0.2302},{"period":"ytd","weight":0.0222}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.0145},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1437},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司，专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症（MS）和神经免疫学；阿尔茨海默病（AD）和痴呆症；神经肌肉疾病，包括脊髓肌萎缩症（SMA）和肌萎缩侧索硬化症（ALS）；运动障碍，包括帕金森氏症；以及眼科学。该公司还专注于在免疫学、神经认知障碍、急性神经学和疼痛等新兴增长领域发现、开发和提供全球创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.039226},{"month":2,"riseRate":0.411765,"avgChangeRate":-0.004843},{"month":3,"riseRate":0.5,"avgChangeRate":-0.023281},{"month":4,"riseRate":0.323529,"avgChangeRate":-0.021192},{"month":5,"riseRate":0.617647,"avgChangeRate":0.03339},{"month":6,"riseRate":0.470588,"avgChangeRate":0.016596},{"month":7,"riseRate":0.676471,"avgChangeRate":0.034715},{"month":8,"riseRate":0.588235,"avgChangeRate":0.030673},{"month":9,"riseRate":0.5,"avgChangeRate":0.023197},{"month":10,"riseRate":0.542857,"avgChangeRate":0.058896},{"month":11,"riseRate":0.6,"avgChangeRate":0.018187},{"month":12,"riseRate":0.457143,"avgChangeRate":0.034185}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}